Surprising Variability in Tryptamine Profiles of Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions. - Sharchaton A; Parsha S; Azerrad SP; Dekel Y; Rabah N; Páleníček T; Kurzbaum E (Journal of fungi (Basel, Switzerland), 2026)

Policy Considerations for Psychedelics in Research and Medicine - What’s Next on the Schedule? - Matthew A. Boehm; Oriana Mayorga (Journal of Science Policy & Governance, 2026)

Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions - Koning Elena; Richard Jérémie; Keshen Aaron (International Journal of Eating Disorders, 2026)

Sexual identity as a moderator of associations between lifetime MDMA/ecstasy or psilocybin use and mental health outcomes: An exploratory analysis of a nationally representative sample using NSDUH 2015-2019 - Seale M. (Research Square, 2026)

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study - University of Wisconsin; Madison (ClinicalTrials.gov, 2026)

Unmixing the psychedelic connectome: Brain network traits of psilocybin - Bhavaraju Krishna Prasad; Mason Natasha L.; Mallaroni Pablo; Heinke Dietmar; Toennes Stefan W.; Ramaekers Johannes G.; Amico Enrico (Network Neuroscience, 2026)

Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study - Meyer Thomas D; Vale Lauren N; Ibrahim Maya; Olmos Carolina; Quevedo João; Soares Jair C (BMJ Open, 2026)

Psilocybin helps woman with Alzheimer's - Busby Mattha (New Scientist, 2026)

Convergent biosynthesis of psilocybin in an ectomycorrhizal lineage: is the psychoactive end-product the selected trait? - Askari M; Surapaneni V. (EcoEvoRxiv, 2026)

Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms - Hummel Haley M.; Obrochta Alexia N.; Kerr David C. R.; Cservenka Anita (Journal of Drug Issues, 2026)

Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review. - Smith SA; Mohammad H; Lee LHN; Dennett L; Smith S; Burback L; Winkler O; Greenshaw A; Jetly R; Kennedy SH; Bhat V; Swainson J; et al. (Psychopharmacology, 2026)

Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms - Centre Hospitalier Universitaire de Nīmes (ClinicalTrials.gov, 2026)

A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD) - Sunstone Medical (ClinicalTrials.gov, 2026)

Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits - Pasquini Lorenzo; Vohryzek Jakub; Escrichs Anira; Perl Yonatan Sanz; Ponce-Alvarez Adrian; Idesis Sebastian; Girn Manesh; Roseman Leor; Mitchell Jennifer M.; Gazzaley Adam; Kringelbach Morten; Nutt David J.; et al. (Human Brain Mapping, 2026)

Raman Activity Investigation and Utilization of Psilocybin - Sun Mingyu; Zhao Xiaoyu; Kong Fandi; Wang Jinsong; Lu Yunchang; Tong Liang (Journal of Raman Spectroscopy, 2026)

Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidence - Sabani Astrit; Khatak Adnan (Annals of Medicine & Surgery, 2026)

Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review - Jalalian-Javadpour Marzieh; Yekta Batool Ghorbani; Reyhani Niloufar; Hajizamani Shadi; Azizi Ali; Azad Najma Khoshrooz; Mohammadi Hamidreza; Vaseghi Salar (Journal of Affective Disorders Reports, 2026)

Daily self-assessment within a regimen of microdosing indicates enhanced psychological functioning on microdosing days relative to non-microdosing days. - St Pierre M; Argento E; Cates J; Kryskow P; Harvey K; Stamets P; Santos-Brault E; Paschall SA; Kuypers KPC; Rootman J; Walsh Z (Psychopharmacology, 2026)

Provider perspectives on challenges in treatment during psychedelic therapy. - Bender DA; Nayak SM; Siegel JS; Hellerstein DJ; Ercal BC; Lenze EJ (Psychopharmacology, 2026)

An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder - Grant Jon E.; Boutouis Sophia; O’Brien Margaret; Avila Laurie; Neelapu Megha; Ehsan Dustin (Clinical Neuropharmacology, 2026)

Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review. - Orsini DK; Wong S; Di Luch S; Chan B; Vasudeva S; Lovell GFM; Le GH; Jones BDM; Chisamore N; Mollica A; Johnson DE; Kaczmarek ES; et al. (JAMA psychiatry, 2026)

Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders - Plourde Louis; Chang Sue-Ling; Nguyen Olivia; Garel Nicolas; Farzin Houman; Stephan Jean-François; Fallu Jean-Sébastien; Dorval Michel (Palliative Medicine, 2026)

MFCC-DFT mapping of ligand recognition at the 5-HT receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics. - Junior WSC; Bezerra KS; Matias EGC; Oliveira JIN; Fulco UL (Physical chemistry chemical physics: PCCP, 2026)

Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats - Allen Josh; Jupp Bianca; Baker Tamara L.; Haskali Mohammad B.; Brkljača Robert; Plummer Zoe; Sun Mujun; Brand Justin; Christie Brian R.; Debert Chantel T.; McDonald Stuart J.; O’Brien Terence J.; et al. (Cell Reports Medicine, 2026)

The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential. - Brar PS; Price RB; Ross S; Tofighi B; Sarpal DK (Journal of psychopharmacology (Oxford, England), 2026)

The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review. - Giaffone de Paiva Ferreira F; Fernandes JAB; Filev R; da Silveira DX; Fidalgo TM (Journal of psychopharmacology (Oxford, England), 2026)

Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis. - Özaydın Y; Canlan Özaydın B (Journal of psychopharmacology (Oxford, England), 2026)

Chemistry/structural biology of psychedelic drugs and their receptor(s). - Gumpper RH; Nichols DE (British journal of pharmacology, 2026)

Psilocybin as a novel treatment for chronic pain. - Askey T; Lasrado R; Maiarú M; Stephens GJ (British journal of pharmacology, 2026)

The Australia story: Current status and future challenges for the clinical applications of psychedelics. - Nutt DJ; Hunt P; Schlag AK; Fitzgerald P (British journal of pharmacology, 2026)

Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT receptor agonists. - Sharp T; Ippolito A (British journal of pharmacology, 2026)

Psychedelics, entactogens and psychoplastogens for depression and related disorders. - Hoyer D (British journal of pharmacology, 2026)

Evidence that 5-HT receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs. - Ippolito A; Vasudevan S; Hurley S; Gilmour G; Westhorpe F; Churchill G; Sharp T (British journal of pharmacology, 2026)

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation? - Qureshi O; Cowley J; Pegg A; Cooper AJ; Gordon J; Brady CA; Belli A; Butterworth S; Upthegrove R; Andrews N; Barnes NM (British journal of pharmacology, 2026)

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology. - Wittenkeller L; Gudelsky G; Winhusen TJ; Amato D (British journal of pharmacology, 2026)

Correction: The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice. - Fleury S; Nautiyal KM (Molecular psychiatry, 2026)

Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway. - Ascone F; Buzzelli V; Mottarlini F; Di Trapano M; Miglioranza P; Rava A; Feo A; Spano F; Hausman M; Sugaya K; Caffino L; Fumagalli F; et al. (Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 2026)

Recreational drug poisonings reported to six European poison centres from 2021 to 2024. - Hondebrink L; Faber K; Kader A; Jagpal PS; Arif T; Hermanns-Clausen M (Clinical toxicology (Philadelphia, Pa.), 2026)

Three cases of wood-lover paralysis: clinical insights from Victoria, Australia. - Silvester A; Hampton S; May TW; Holmes GD; Leang YH (Clinical toxicology (Philadelphia, Pa.), 2026)

Psychedelics as a potential treatment for borderline personality disorder: A narrative review. - Artna E; Sandhu G; Chisamore N; Lipsitz O; Kaczmarek ES; Johnson DE; Rosenblat JD; Sediqzadah S (Psychiatry research, 2026)

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants - Arikci Denis; Borgulya Joran; Straumann Isabelle; Vizeli Patrick; Luethi Dino; Thomann Jan; Rudin Deborah; Vukalovic Ina; Eckert Anne; Liechti Matthias E.; Holze Friederike (Neuropsychopharmacology, 2026)

Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia. - Giri Y; Furst P; Loo CK; Clark SR; Tibrewal P (The Australian and New Zealand journal of psychiatry, 2026)

The relevance of the 5HT2A-mGlu2 heterodimer in explaining the clinical ambivalence of psilocybin - Escobar-Cornejo Guillermo; Corredor-Gamba Julián; Rodriguez-Rojas Yoly; Cárdenas F. P. (Revista de Neuro-Psiquiatría, 2026)

Study Protocol for “Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults” - Sjöström David; Schau Rybäck Olea; Claesdotter Knutsson Emma; Kajonius Petri; Jensen Sondén Oskar; Carlbring Per; Björkstrand Johannes; Movahed Rad Pouya (PLOS One, 2026)

Chemical ecology and convergent evolution of natural hallucinogens: From ecological defense to conserved neural targets. - Wang Y; Wang H; Lin C; Wang X (Proceedings of the National Academy of Sciences of the United States of America, 2026)

Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations. - Estela-Fernandez CA; Mohamed Yousif Elsheikh R; Beatrice DB; A Alhendal A; Irene Ewe C; Montesinos SY; Wensel J; Mishra AP; Yousif AA; Ali HT (Neuropsychiatrie: Klinik, Diagnostik, Therapie und Rehabilitation: Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater, 2026)

Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development - Stefanie Enriquez Geppert; Lisa Bevers; Arvid Rosander; Peter Fodran; Vince Polito (University of Groningen research database (University of Groningen / Centre for Information Technology), 2026)

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder - Johns Hopkins University (ClinicalTrials.gov, 2026)

Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex - Du Yingjie; Zhao Xiangting; Yao Yishan; Li Yunfeng; Wang Guyan; Zhang Liming (Journal of Psychopharmacology, 2026)

Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial - Unity Health Toronto (ClinicalTrials.gov, 2026)

Divergent changes in perturbation-induced brain reconfiguration following depression treatment with psilocybin and escitalopram - Dagnino PC; Acero-Pousa I; Carhart-Harris RL; Erritzoe D; Nutt DJ; Kringelbach ML; Perl YS; Deco G. (bioRxiv, 2026)

Anthracaurisin A─Discovery of a Cytotoxic -Sesquiterpene Dimer from Patagonian. - Petit B; Michrafy I; Nafie J; Dyer GE; Marshall EM; Riquelme C; Cabrera-Pardo JR; Strother JA; Loesgen S (Journal of natural products, 2026)

Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2026)

A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD) - Anthony P King (ClinicalTrials.gov, 2026)

Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions. - Guidetti C; Fava M; Papakostas GI (Molecular psychiatry, 2026)

PSILOCYBIN IN THE TREATMENT OF DEPRESSIVE DISORDERS: CLINICAL EVIDENCE AND ITS POTENTIAL TO ADDRESS THE GLOBAL MENTAL HEALTH CRISIS - A REVIEW - Łoś Aleksandra; Szkodziński Kacper; Jakubczyk Inga; Maternia Jagoda; Majowicz-Czaszyńska Karolina; Pempuś Wiktoria; Król Nikola; Tomaszek Barbara; Blok Aleksandra; Wiater Dominik; Płodzień Gabriela (International Journal of Innovative Technologies in Social Science, 2026)

Multi-metric evaluations of acute psychedelic effects on fMRI brain entropy. - McCulloch DE; Olsen AS; Ozenne B; Larsen K; Stenbæk DS; Armand S; Madsen MK; Knudsen GM; Fisher PM (Nature communications, 2026)

Psychedelics and autism spectrum disorder: Mechanistic insights, translational evidence and ethical challenges. - Claudino Dos Santos JC; Bolan SJ; Lodetti G; Viana GL; Rico EP; Gonçalves CL (Journal of psychiatric research, 2026)

Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care - Mauro Pettorruso; Giacomo d’Andrea; Antonio Inserra; Clara Cavallotto; Stefano Censi; Étienne Billard; Antonio Di Stefano; Luisa De Risio; Maria Giulia Tullo; Claudio D’Addario; Giorgio Di Lorenzo; Richard G. Wise; et al. (Translational Psychiatry, 2026)

Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study - Yale University (ClinicalTrials.gov, 2026)

Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial - University Health Network; Toronto (ClinicalTrials.gov, 2026)

Psilocybin-Assisted Therapy for Prolonged Grief - University of Virginia (ClinicalTrials.gov, 2026)

Blocking 5-HT2B receptors abolishes psilocybin's efficacy in the rat forced swim test. - Seillier L; Seillier A; Zvolska MA; Šlamberová R (Journal of psychopharmacology (Oxford, England), 2026)

Cardiovascular effects associated with acute recreational drug toxicity presentations to the emergency department: a European drug emergencies network (Euro-DEN plus) study. - van den Busken WJ; Dines AM; Eyer F; Heyerdahl F; Hovda KE; Liechti ME; Miró Ò; Vallersnes OM; Wood DM; Yates C; Dargan PI; (on behalf of the Euro-DEN Plus Research Group); et al. (Clinical toxicology (Philadelphia, Pa.), 2026)

Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy - Johns Hopkins University (ClinicalTrials.gov, 2026)

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label Trial - University Health Network; Toronto (ClinicalTrials.gov, 2026)

Psychedelics and related compounds in cluster headache and migraine: a systematic review and meta-analysis v1 - Racca Camille; Cordier Cécilie (protocols.io, 2026)

Serotonergic psychedelics for Autism spectrum disorder: Neurobiological mechanisms and translational prospects. - Low ZXB (Progress in neuro-psychopharmacology & biological psychiatry, 2026)

Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes - Frick A; Blest-Hopley G; Grin M; Erritzoe D; Nutt D; Carhart-Harris R. (Research Square, 2026)

Psychedelic Use, Microdosing, Motives, and Information and Product Sources Among Young Adults in the United States. - Berg CJ; McCready DM; LoParco CR; Schubel LC; Romm KF; Thakkar S; Williams J; Cavazos-Rehg PA; Yang YT (Journal of psychoactive drugs, 2026)

DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in Zebrafish - Dong Mengxuan; Zhang Yi; Cao Manzhu; Shi Tong; Li Liqin; Zong Xingxing; Wang Chen (Molecules, 2026)

“I even saw four deer grazing”: online-offline entanglements in the psilocybin pluriverse - Wanke Michał; Matuszewski Paweł; Siuda Piotr (OSF Preprints, 2026)

Beyond Psychedelic Microdosing: Therapeutic Potential, Neuropharmacology, and Safety Considerations in Low-Dose Psychoactive Use - Eric P. Rubenstein (Journal of Advances in Developmental Research, 2026)

Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico - Leeman Lawrence; Armstrong Maya; Menashi Dara; Nayo-Washington Hanifa; Marseille Elliot; Herrera Janus; Romero Crystal; Page-Reeves Janet (Frontiers in Public Health, 2026)

Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics. - Bhat A; Zolali E; Sakib MA; Rahimian M; McMahon LR; German N; Obeng S (ACS chemical neuroscience, 2026)

Distinct brain responses to psilocybin and escitalopram in depression captured by the Fluctuation-Dissipation Theorem - Dagnino PC; Acero-Pousa I; Zamora-López G; Escrichs A; Erritzoe D; Nutt DJ; Carhart-Harris RL; Sanz Perl Y; Kringelbach ML; Deco G. (bioRxiv, 2026)

Psychedelics disrupt hierarchical cortical propagations in the default mode network of humans and mice. - Pines AR; Zhang X; Kochalka J; Vesuna SS; Kauvar IV; Rajasekharan D; Reneau TR; Akiki TJ; Hack LM; Siegel JS; Williams LM (Proceedings of the National Academy of Sciences of the United States of America, 2026)

The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function - Manoj Doss (ClinicalTrials.gov, 2026)

Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARA - SAIMSARA (SAIMSARA Journal, 2026)

Efficacy of Psilocybin-Assisted Therapy in Major Depressive Disorder: A Systematic Review and Meta-Analysis - Labra-Lorenzana Angel; Lima-Sánchez Dania Nimbe; Delaflor-Wagner Christian Alejandro; Martínez-Hernández Diana; Ramos-Jiménez Christian; Toledo-Lozano Christian Gabriel (Psychiatry International, 2026)

Psychedelics relax predictive processing in the post-acute period by remodeling cortico-cortical feedback circuits. - West CL; Imai F; Bastos G; Hornick MA; Rachmany L; Duran A; Nadeem S; Ricci D; Rader Groves AM; Wargo JA; Leeuwen NV; Sershen H; et al. (bioRxiv: the preprint server for biology, 2026)

THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRY - Julia Osipowska; Marlena Kwolek; Alicja Judzińska; Bartosz Piech; Kamila Sobczyńska; Justyna Ignarska; Magda Terbosh; Sabina Kubicz `Mzabi; Emilia Trojanowska; Magdalena Dubaj (International Journal of Innovative Technologies in Social Science, 2026)

Dextromethorphan Beyond the Cough: Exploring Its Psychedelic Potential: A Systematic Review - Edward P. Hackett; Aditi Chaudhri -; Linda Hasman; Rajbala Thakur; Michael Scott; Robert H. Dworkin (CNS Drugs, 2026)

Integrating psychedelic-assisted psychotherapy into addiction care in the Czech Republic: Clinical evidence, safety, and regulatory developments - Zuzana Postránecká; Matyáš Lucký; Viktor Mravčík; Tomáš Páleníček (Journal of Psychedelic Studies, 2026)

Altered States, Enhanced Potential: Psychedelics and Physical Performance - Zane Qarni; Jeremie Richard (PsyArXiv, 2026)

EEG microstate dynamics during psilocybin intoxication relate to acute experience and persisting psychological changes - Jajcay N; Vejmola Č; Korčák J; Tylš F; Viktorinová M; Viktorin V; Bravermanová A; Androvičová R; Balíková M; Horáček J; Brunovský M; Hlinka J; et al. (bioRxiv, 2026)

Overcoming Pharmacokinetic and Peripheral Safety Challenges in Psychedelic Therapies: The Promise of Advanced Drug Delivery Systems. - Zhang T; Lin C; Wang X (ACS pharmacology & translational science, 2026)

Aquahenosis: A non-pharmacological altered state of consciousness induced by Floatation-REST in individuals with anxiety and depression - Theo Tobel; Aidan Cone; Emily M Choquette; McKenna Garland; Micah Johnson; Keller Mink; Caitlin Lynch; Joel Frohlich; Justin Feinstein; Nicco Reggente (PsyArXiv, 2026)

The effects of psychedelics on attention deficit and hyperactivity disorder - a systematic review. - Raikkerus H; Bujour A; Kennedy M; Tiihonen J (Acta neuropsychiatrica, 2026)

Psilocybin-assisted Physiotherapy for Refractory Motor Functional Neurological Disorder: A Randomized Dose-comparison Pilot Study (P7-17.001) - Bryson Alexander; Bhagavan Chiranth; Carter Olivia; Nielsen Glenn; Berlowitz David; Issak Sara; Attard Zachary; Eleftheriadis Dina; Oliver Gina; Mayne Deanne; Roebuck Greg; Rucker James; et al. (Neurology, 2026)

Alcohol consumption and substance use among French medical students: A nationwide cross-sectional study: Consommation d'alcool et de substances chez les étudiants en médecine de France: une étude transversale nationale. - Gillet M; Doudeau N; Vilain F; Sadat K; Morvan Y; Frajerman A (Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2026)

A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease - Jennifer Mitchell (ClinicalTrials.gov, 2026)

Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-sampling - Robin Carhart-Harris; PhD; MA (ClinicalTrials.gov, 2026)

Correction to: Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action - Reid Matthew J.; Kettner Hannes; Blanken Tessa F.; Weiss Brandon; Carhart-Harris Robin (Current Psychiatry Reports, 2026)

Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticity - Ahmadian-Moghadam Samaneh; Roshan-Milani Shiva; Saboory Ehsan (Translational Psychiatry, 2026)

Developing Methods for Observing Awe Narration in Psilocybin-Assisted Therapy - Tarbi Elise C.; Bhatia Ian; Balach Nabil; Buehler Suzannah; Demeo-Meres Magdalena; Gramling Cailin; Thambi Tej; Hart Julia; Reblin Maija; Rizzo Donna M.; Gramling Robert; Agrawal Manish; et al. (Healthcare, 2026)

Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study - Yale University (ClinicalTrials.gov, 2026)

2 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy Volunteers - Robin Carhart-Harris; PhD; MA (ClinicalTrials.gov, 2026)

Studies on enzymatic hydrolysis of psilocin- O -glucuronide for screening of psilocin in human urine by liquid chromatography-triple quadrupole tandem mass spectrometry - Barajas David A; Carter Heather C Noda; Tomedi Michael R; Lam Hiu Yu; Deloatch Tiffany N; Reynolds Gregory D; Castaneto Marisol S; Ke Pucheng (Journal of Analytical Toxicology, 2026)

Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation - Dorval Michel; Audet-Croteau Virginie; Chang Sue-Ling; Masse-Grenier Marianne; Tremblay Annie; Bénard Elodie; Chapdelaine Alexandra; Garel Nicolas; Guertin Jason Robert (Healthcare, 2026)

The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults - University of Calgary (ClinicalTrials.gov, 2026)

Prolonged Grief Symptom Outcomes During At-Home Ketamine-Assisted Therapy: A Real-World Retrospective Analysis of 503 Adults - Carter D; Reardon I; Swain J; Vando L. (Research Square, 2026)

Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland. - Kelly JR; Sheridan C; Iusan P; Coakley L; Burke L; Brennan C; MacDonald A; Ivers JH; Trepel D; Tormey G; Finnegan M; Young GW; et al. (The international journal of neuropsychopharmacology, 2026)

Time to embrace the whole: considering the replacement of psilocybin with Psilocybe spp. in psychedelic research and therapy - Ona Genís; Llagostera Cristina; Alvarez Oscar; Dueñas Rosa M.; González Debora; Soto-Angona Oscar (Natural Product Research, 2026)

One dose of Psilocybin modulates Brain Activity among Depressive patients: Preliminary Neuroimaging Results from the PSILODAC Study - Pastre M.; Pereira F.; Gibert T.; Giron A.; Goemare B.; Olié E.; Courtet P.; Lopez-Castroman J.; Conejero I. (European Psychiatry, 2026)

A Molecule-Resolved Bibliometric Analysis of PubMed-Indexed Psychedelic Research (2015-2025): Volume, Temporal Trends, and Publication Types - M. Pastuszak; K. Jakuszkowiak-Wojten; M. Gałuszko-Węgielnik; A. W. Kwaśny; A. Mechlińska; D. Świeczkowski; W. J. Cubała (European Psychiatry, 2026)

From Altered States to Altered Trajectories and From Molecules to Meaning: A Network Meta Analysis Mapping Comparative Efficacy of Psychedelic Assisted Therapies in Modern Psychiatry - Gaurav Uppal; Naima Gul; Asha Dhandapani; Sathyan Soundararajan; Khushboo Kansal (BJPsych Open, 2026)

Acute Hallucinogen Intoxication Following Ingestion of a Commercially Available Mushroom Extract Product: A Case Report. - Udoro AJ; Yukyi Y; Ansari AZ; Gandara HA; Ahmed F; Hunt D (Cureus, 2026)

Patient perceptions towards psychedelics for musculoskeletal pain: A cross-sectional survey - Li EJ; Mosharraf B; Ali H; Noyes M; Doshi P; Wallace C; Petranker R; Adili A; Khan M; Busse JW; MacKillop J; Madden K. (medRxiv, 2026)

Psilocybin shows rapid relief for depression symptoms - Canady Valerie A. (Mental Health Weekly, 2026)

Impact of formulation variables on the quality attributes of psilocybin-loaded oral thin films for early-phase development - Wongumpornpinit Vorawut; Ingkaninan Kornkanok; Temkitthawon Prapapan; Waranuch Neti; Copetti Pivetta Rhannanda; Zuo Jieyu; Araujo Gabriel Lima Barros de; Bou-Chacra Nádia; Somayaji Vijay; Loebenberg Raimar (Journal of Drug Delivery Science and Technology, 2026)

EE127 A REVIEW OF HEALTH ECONOMIC ANALYSES OF PSILOCYBIN, MIDOMAFETAMINE(MDMA), AND KETAMINE-BASED TREATMENTS FOR MENTAL HEALTH CARE - Sidovar Matthew; O'Connor Shane J.; Orsini Lucinda (Value in Health, 2026)

Demoralization in Psilocybin-Assisted Therapy for Advanced Cancer: An Exploratory Network Analysis - Mallard Austin; Harbour Jessica; Pappano Catherine; Mancuso Mary; Kilbourn Kristin; Fischer Stacy M. (Journal of Pain and Symptom Management, 2026)

EE341 COST-EFFECTIVENESS OF PSILOCYBIN-ASSISTED THERAPY (PAT) FOR PATIENTS WITH TREATMENT-RESISTANT DEPRESSION - Ziadi Yosr; Park Taehwan (Value in Health, 2026)

Psilocybin: Chemical Foundations and Emerging Therapeutic Potential - Patil Shivaputra A.; Hunsberger Holly C. (Mini-Reviews in Medicinal Chemistry, 2026)

Comparing Cannabis Use Motivations and Dependence Across Regular Cannabis Users Who Have or Have Not Recently Used Psilocybin. - Stanger MK; Soffer HO; Bryan AD; Skrzynski CJ (Cannabis and cannabinoid research, 2026)

Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin. - Mallaroni P; Singleton SP; Mason NL; Satterthwaite TD; Ramaekers JG (Molecular psychiatry, 2026)

Therapeutic effects of psilocybin in major depressive disorder: a systematic review and meta-analysis exploring dose effects. - He Z; Wang Y; Chen J; Cheng J; Feng Y; Niu S; Yan J (European archives of psychiatry and clinical neuroscience, 2026)

Sex-dependent developmental changes in behavior, brain structure, functional connectivity, and sensory perception following exposure to psilocybin during adolescence. - Sahoo I; Masadi S; Maheswari A; Utama R; Abeer MI; Soltanpour S; Nasseef MT; Chukwuemeka T; Sinhal N; Pandit J; Ortiz RJ; Cavallaro N; et al. (Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 2026)

Lifetime psychedelic use and opioid use disorder severity in a National Survey: the roles of psychedelic type and mental health. - Ehmann S; Hager NM; Regier PS; Jones G; Allen JJB (Addictive behaviors, 2026)

Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations - Yonezawa Kengo; Hirata Mayuko; Takano Hiroaki; Kusudo Keisuke; Tomiyama Sota; Harada Lisa; Suzuki Kouta; Nutt David J.; Uchida Hiroyuki; Tani Hideaki (Psychiatry and Clinical Neurosciences, 2026)

Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review. - Sabé M; Grof P; Sackett NB; Tai S; Kryskow P; Bershad A; Turkington D; Buonarroti M; De Pieri M; Baniotopoulos P; Eskinazi M; Böge K; et al. (Schizophrenia research, 2026)

Mapping cognitive-behavioral approach in psychedelic-assisted treatment: a systematic review across phases with classic and non-classic psychedelics. - Varela YM; de O Tavares VD; Delgado LM; de Faria HAT; Menezes LQ; Almeida RM; Agrícola P; de Carvalho BS; Bienemann B; Falchi-Carvalho M; Cavalcanti-Ribeiro P; Palhano-Fontes F; et al. (European archives of psychiatry and clinical neuroscience, 2026)

Suggested Guidelines for Applying a Systemic Lens to Psychedelic-Assisted Psychotherapy. - Lappan SN; Davis SD (Psychedelic medicine (New Rochelle, N.Y.), 2026)

Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [F]FDG-PET study. - Egger K; Bozsak R; Aicher HD; Sari H; Poetzsch SN; Rominger A; Martin-Soelch C; Smallridge JW; Dornbierer D; Quednow BB; Scheidegger M; Cumming P (Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism, 2026)

Psilocybin Decreases Preference for Large Rewards Accompanied by Increased Activity of Parvalbumin Neurons With Perineuronal Nets in the Medial Prefrontal Cortex - Houff Jenna; Williams Andrew; Allen Obie; Gisabella Barbara; Pantazopoulos Harry; Del Arco Alberto (European Journal of Neuroscience, 2026)

Reorganization of Human Brain Waves Across Diverse States of Consciousness. - Fotiadis P; Jang H; Dai R; Li D; Cofré R; Timmermann C; Mashour GA; Hudetz AG; Huang Z (bioRxiv: the preprint server for biology, 2026)

Hallucinogen-Assisted Psychotherapy for Trauma Disorders: A Bionian Lens. - Miller CWT; Kozak Z (Psychodynamic psychiatry, 2026)

Expectations and Motivations for Participation in Clinical Trials Utilizing Psychedelics for Treatment-Resistant Depression: A Qualitative Study. - Poppe C; Lyck L; Bechtold L; Repantis D (Brain and behavior, 2026)

Meaning-Centered Psychotherapy for Psilocybin-Assisted Therapy Among Patients with Advanced Cancer and Depression: Rationale and Preliminary Evaluation of MCP-PSIL. - Rosa WE; Napolitano S; McAndrew N; Jenkins B; Lichtenthal WG; Applebaum AJ; Breitbart W; Agrawal M (Psychedelic medicine (New Rochelle, N.Y.), 2026)

Therapeutic advances in fibromyalgia: one year in review 2026. - Bazzichi L; Di Carlo M; Salaffi F; Farah S; Porta F; Ablin JN; Varrassi G; Galli F; Fornasari D; Carotti M; Alciati A; Pellegrino G; et al. (Clinical and experimental rheumatology, 2026)

Psychedelic Therapy and the Role of Music: A Scoping Review of Quantitative Evidence on Subjective and Objective Outcomes. - Rowe T; Hurzeler T; Towers E; Louie E; Morley KC (Brain and behavior, 2026)

Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression - Kaczmarek Erica S.; Rodrigues Nelson B.; Chisamore Noah; Doyle Zoe; Meshkat Shakila; Blainey Marc G.; Brudner Ryan; Ali Shaun; Teopiz Kayla M.; McIntyre Roger S.; Rosenblat Joshua D. (Journal of Affective Disorders, 2026)

Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial - Weintraub Marc J.; Jeffrey Jessica K.; Ichinose Megan C.; Bergman R. Lindsey; Shapiro Benjamin; Barnett Gregory; Artin Hewa; Lynn Marc; Salimian Anabel; Grody Shelby; Ramesh Rahul; Eales Lauren; et al. (Journal of Affective Disorders, 2026)

Psilocybin restores behavioral and neuroplastic deficits induced by chronic stress in rats - Bysiek Agnieszka; Szpręgiel Izabela; Wojtas Adam; Maćkowiak Marzena; Wawrzczak-Bargieła Agnieszka; Leśkiewicz Monika; Trojan Ewa; Kamińska Katarzyna; Kumorek Weronika; Bilecki Wiktor; Gołembiowska Krystyna (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2026)

U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey. - Priest M; Kilmer B; Senator B; Setodji CM (Rand health quarterly, 2026)

Effect of psilocybin-assisted psychotherapy on anxiety symptoms: A systematic review and meta-analysis - Hood Alex; Elkins Gary (Journal of Psychedelic Studies, 2026)

Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache - Brendstrup-Brix Kristoffer; Ozenne Brice; Fisher Patrick M.; Stenbæk Dea S.; Petersen Anja S.; Armand Sophia; McCulloch Drummond E-Wen.; Marstrand-Joergensen Maja Rou; Ulv Larsen Sara M.; Johansen Annette; Jensen Rigmor H.; Knudsen Gitte M.; et al. (Journal of Psychopharmacology, 2026)

A spatiotemporal gating hypothesis for psilocybin plasticity: reconciling the 5-HT₂A-TrkB mechanistic paradox - Pei Gang (Cell Discovery, 2026)

Psychedelic-induced hypomania and mania: a systematic review and meta-analysis. - Eskinazi M; Nasserdine R; Cusin RM; Baniotoupoulos P; Saccaro LF; De Pieri M; Corino T; Seragnoli F; Briefer JF; Aboulafia Brakha T; Richard-Lepouriel H; Penzenstadler L; et al. (Molecular psychiatry, 2026)

Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers. - L Belinger; N M Rieser; E J E Engeli; L Becciolini; M Clamote; M Pribis; F Saissi; G.A. Florineth; N L Hehl; M Herdener; K H Preller (Open Access CRIS of the University of Bern, 2026)

Rapid and Sensitive Detection of Psilocybin and Psilocin in Urine by Surface-Enhanced Raman Spectroscopy - Lin Wei; Chen Hong; Li Yuanyuan (Journal of Raman Spectroscopy, 2026)

Psilocybin-induced neurocardiogenic syncope: a case report - Atiq Mazen A.; Weisman Eli; Guerra Rodrigo B.; Martinez Luis Luna; Yaden David B.; Barrett Frederick S.; Nayak Sandeep; Sayali Ceyda (Psychopharmacology, 2026)

Retail Availability of Intoxicating Cannabis and Mushroom Products Across Eleven U.S. Cities: Sales Persist Despite Prohibitions. - LoParco CR; Rossheim ME; Tillett KK; Cui Y; Johnson M; Speer M; Mihelich D; Amdeta H; Ndisebuye D; Berg CJ (Journal of studies on alcohol and drugs, 2026)

Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration: a case report - Lago Marcos; Cerveira Mariana; Simonet Joe Xavier (Frontiers in Neuroscience, 2026)

Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia - NYU Langone Health (ClinicalTrials.gov, 2026)

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial - Mertens Lea J.; Betzler Felix; Brand Manuela; Evens Ricarda; Jungaberle Andrea; Jungaberle Henrik; Kärtner Laura; Majić Tomislav; Schmitz Christian N.; Ströhle Andreas; Scharf Dennis; Spangemacher Moritz; et al. (Psychotherapy and Psychosomatics, 2026)

Catatonia Associated With First-Time Psilocybin Exposure: A Case Report - Singh Jasbir; Mruthyunjaya Pranathi (Cureus, 2026)

The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD - Emory University (ClinicalTrials.gov, 2026)

Environmental and Internal Gating of Memory: ARCH Multiplicative Threshold Framework for Encoding and Retrieval - Rahman T. (Preprints.org, 2026)

Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder - Urban Marvin M.; Zillich Lea; Rieser Nathalie M.; Herdener Marcus; Spanagel Rainer; Vollenweider Franz X.; Preller Katrin H.; Meinhardt Marcus W. (Translational Psychiatry, 2026)

Active placebo control interventions in pharmacological trials: a scoping review of the development process and a terminological analysis. - Laursen DRT; Salazar J; Jürgens G; Hróbjartsson A (Journal of clinical epidemiology, 2026)

Serotonergic Psychedelics as a Potential Therapeutic Strategy for Anxiety, A Systematic Review - Naja Bralic; Elena Bragagnolo; Mikael Palner (PsyArXiv, 2026)

Psilocin glucuronide in whole blood: a stable and useful biomarker of psilocybin intake - Bergh Marianne Skov-Skov; Bogen Inger Lise; Vevelstad Merete; Øiestad Åse Marit Leere (Journal of Analytical Toxicology, 2026)

Psilocybin for Treatment-Resistant Depression: A Comprehensive Review of Mechanisms and Therapeutic Potential - Dallas T Mason (Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg), 2026)

The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A New and Promising Approach - Rachel N Clark (Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg), 2026)

Psilocybin-Assisted Therapy in the Management of Anxiety and Depression Among Cancer Patients - Caleb Lemus (Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg), 2026)

Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot Trial - University of Colorado; Denver (ClinicalTrials.gov, 2026)

Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder - University of New Mexico (ClinicalTrials.gov, 2026)

PsiConnect: Multimodal Neuroimaging of Context-Dependent Brain and Behaviour Dynamics under Psilocybin - Novelli Leonardo; Stoliker Devon; Barta Tamrin; Greaves Matthew D.; Chopra Sidhant; Jackson James; Kwee Jessica; Pang James C.; Williams Martin L.; Razi Adeel (Scientific Data, 2026)

Mescaline Alters Cerebellar Function, Global Connectivity, and Frequency-Selective Acoustic Gating: A BOLD fMRI Study in Awake Rats. - Cavallaro N; Rai P; Akins D; Soltanpour S; Nasseef MT; Ortiz RJ; Utama R; Cody CR; Mistry A; Brenhouse HC; Kulkarni PP; Ferris CF (Neuroscience bulletin, 2026)

A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression - Washington University School of Medicine (ClinicalTrials.gov, 2026)

265 Self-reported rates of psilocybin use in North Florida, 2012 to present - Millay T; Kodali M; Cottler L. (Journal of clinical and translational science, 2026)

361 Effect of intravenous psilocybin on mechanical hypersensitivity in a rat model of reserpine-induced chronic centralized pain - Huels E; Smith S; Liu T; Pal D. (Journal of clinical and translational science, 2026)

Psilocybin-assisted Cognitive Behavioral Therapy for Depression - University of California; Los Angeles (ClinicalTrials.gov, 2026)

Ancient Wisdom, Modern Questions: Western and Orthodox Christianity Engage Psychedelic Spirituality - Geoffrey Ready; Ron Cole-Turner (Religions, 2026)

Psilocybin-facilitated Treatment for Cocaine Use - University of Alabama at Birmingham (ClinicalTrials.gov, 2026)

Appetite for change: How psilocybin reshapes food reward learning through striatal dopamine function - Conn K; Wong N; Sunnetci S; Al Siyabi A; McCoy K; Huang K; Greaves E; Milton LK; Kuhlmann L; Maguire S; Foldi CJ. (bioRxiv, 2026)

Association Between Lifetime Hallucinogen Use and Valvular Heart Disease: Findings from the All of Us Research Program. - Yang KH; Rasmussen M; Bhatt K; Satybaldiyeva N; Kepner W; Moore AA; Bergstrom J (Journal of psychoactive drugs, 2026)

Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression - Yngwe Hampus; Plavén-Sigray Pontus; Ekman Carl Johan; Henje Eva; Berglund Anders; Tiger Mikael; Beckman Maria; Lundberg Johan (JAMA Network Open, 2026)

Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY) - Alan Davis (ClinicalTrials.gov, 2026)

Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence - University of Calgary (ClinicalTrials.gov, 2026)

Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial. - Jacob Cohen; Peter Parbo; Per Trads Ørskov; Dirk Wildgruber; Benjamin Kreifelts; ulrich kirk; Oke Gerke; Martin Korsbak Madsen; Mikael Palner (PsyArXiv, 2026)

Synthesis of Amines for Active Pharmaceutical Ingredients Using the Whole-Cell Factory Saccharomyces Cerevisae. - Kwiatos N; Ossel S; Mutti FG (Chembiochem: a European journal of chemical biology, 2026)

Psilocybin-Assisted Therapy for Adolescent Anorexia Nervosa: Clinical Considerations and Emerging Models of Care - Geller Jamarie A.; Pacilio Rachel; Downey Amanda E.; Ragnhildstveit Anya; Raymond-Flesch Marissa; Knatz-Peck Stephanie; Gukasyan Natalie (Current Psychiatry Reports, 2026)

Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation - Vaart Andrew van der; LaPratt Jeffrey; Swartz Kimberly; Shoultz Audrey; Lauterbach Margo; Suppes Trisha; Sackeim Harold A.; Aaronson Scott T. (The Journal of Clinical Psychiatry, 2026)

Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization - Yu Feliciano; Tafur Joe; Moreno Francisco; Dahmer Stephen (Frontiers in Psychiatry, 2026)

Psilocybin for Treatment of Obsessive Compulsive Disorder - Francisco A Moreno (ClinicalTrials.gov, 2026)

Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based Sample - University of Wisconsin; Madison (ClinicalTrials.gov, 2026)

A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder - COMPASS Pathways (ClinicalTrials.gov, 2026)

Rapid-acting interventions in treatment-resistant depression - a comparative review of esketamine and psilocybin - Kosiarski Bartłomiej; Skrzypek Anna; Markowicz Patrycja; Zbrożek Mikołaj; Biłyk Krzysztof; Hutkowski Maciej; Chwostek Zuzanna; Maruchniak Hanna; Marzec Wiktoria; Biedroń Paulina (Journal of Pre-Clinical and Clinical Research, 2026)

Treatment-Resistant Depression in the 21st Century: A Scoping Review of Psychedelics and Neuromodulation in Transforming Care - Khadija Kamene (Premier Journal of Neuroscience, 2026)

Psychedelic Use and Missed Needed Mental Health Treatment: Gender Differences in Unmet Perceived Need for Care - Sean M. Viña (Psychoactives, 2026)

Safety and Efficacy of Psilocybin in the Management of Treatment-Resistant Depression: A Systematic Review - Walters CK; Chetty S; Rants’o TA; Gossayn S; Lerotholi LJ. (Research Square, 2026)

From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical Practice - Jessie Kim; Liam Lochhead; Cory R. Weissman (Pharmacology Research & Perspectives, 2026)

The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD. - University Medical Center Groningen (ClinicalTrials.gov, 2026)

Characterizing Resting-State Brain Dynamics with Frequency-Resolved EEG Microstates: Parallel Analyses of Psilocybin Microdosing and Acute Inhaled DMT - Tarailis P; Griskova-Bulanova I. (bioRxiv, 2026)

1020 Long-term Impact of Psilocybin Administration on Sleep-Continuity via Wearable Sensor Time-series: Preliminary-results in Post-Treatment Lyme Disease - Reid Matthew; Yaffe Abigail; Geithner Ian; Rebman Alison; Aucott John; Garcia-Romeu Albert (SLEEPJ, 2026)

1080 Psilocybin Elicits Non-Linear Night to Night Changes in Sleep Spectral Power - Reid Matthew; Weisman Eli; Martinez Luis Luna; Coon William; Barrett Frederick (SLEEPJ, 2026)

0408 Insomnia Severity Differences by Psilocybin, LSD, and DMT Use Status Among Young Adult Daily Cannabis Consumers in the Herbal Heart Study - Vidot Denise; Diggs Bria-Necole; Baral Amrit; Thompson Michelle; Jean-Louis Girardin (SLEEPJ, 2026)

Neural correlates of insight on psilocybin: a within-subjects, healthy volunteer study - Pasquini Lorenzo; Girn Manesh; Kettner Hannes; Ostrand Avery; Allison Kate; Valtierra Christian; Lucas Will; McConnell Patrick; Miller Catriona; Griffith Sydney; Weinstein Dawn; Anderson Brian; et al. (JoCN Forum, 2026)

Exploring new avenues: Psychedelic-assisted therapy for young people. - Vamvakopoulou IA; Nicholls D; Nutt DJ; Di Simplicio M (British journal of clinical pharmacology, 2026)

Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2026)

Psilocybin-Assisted Therapy in Depressive Disorders: Efficacy, Safety, and Persistence of Clinical Effects - A Narrative Review - Zachar Kinga; Sito Maksymilian; Jurkowski Filip; Wójcik Łukasz; Gawron Natalia; Bojanowski Hubert Tomasz; Dobracka Aleksandra; Marczak Zuzanna; Jarowicz Monika; Czmyr Jędrzej (Journal of Education, Health and Sport, 2026)

Psilocybin in the Treatment of Cocaine Use Disorder - Hendricks Peter S.; Lappan Sara N.; Shelton Richard C.; Lahti Adrienne C.; Cropsey Karen L.; Johnson Matthew W.; Bradley Melissa; Simonsson Otto; Davis Lori L.; Grossman Daniel H.; Ortiz Cynthia E. (JAMA Network Open, 2026)

Pilot Results for Psilocybin-Assisted Psychotherapy for Cocaine Use Disorder-A Critical Appraisal - Bonar Erin E. (JAMA Network Open, 2026)

The magic of mushrooms: psilocybin influences behavior in the mangrove rivulus fish, Kryptolebias marmoratus - Forsyth Dayna; Faraone Nicoletta; Lamarre Simon G.; Currie Suzanne (Frontiers in Behavioral Neuroscience, 2026)

Announcement of special issue: ‘Behavioural pharmacology of ketamine and psychedelic drugs’ - Bart A. Ellenbroek; Gernot Riedel (Behavioural Pharmacology, 2026)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer - Sunstone Medical (ClinicalTrials.gov, 2026)

Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study - University of North Carolina; Chapel Hill (ClinicalTrials.gov, 2026)